open access

Vol 51, No 4 (2020)
Untitled
Published online: 2020-12-01
Submitted: 2020-06-14
Get Citation

Eltrombopag use in chronic immune thrombocytopenia of childhood: results from nationwide therapeutic program

Monika Richert-Przygońska, Ewa Demidowicz, Natalia Bartoszewicz, Krzysztof Czyżewski, Mariusz Wysocki, Jan Styczyński
DOI: 10.2478/ahp-2020-0039
·
Acta Haematol Pol 2020;51(4):226-229.

open access

Vol 51, No 4 (2020)
Untitled
Published online: 2020-12-01
Submitted: 2020-06-14

Abstract

Background

Thrombopoietin receptor agonists have been repeatedly confirmed to be safe, efficient, and well tolerated in pediatric patients with chronic immune thrombocytopenia (cITP).

Material and methods

In this report, we present data summarizing the Polish experience of the use of eltrombopag in cITP patients, refractory to standard first-line care. Our analysis was based on clinical and epidemiological data from the Nationwide Therapeutic Program 2018–2020. Quality of the response to the eltrombopag treatment was defined according to the International Consensus Guidelines as follows: complete response (CR) defined as platelet count (PLT) ≥100 × 10/L and absence of bleeding; response (R) defined as PLT ≥30 × 10/L and at least two-fold increase in the baseline count and absence of bleeding.

Results

We evaluated 60 patients (33 boys and 27 girls) with chronic and refractory ITP. Median age at beginning of treatment was 9.5 years. Median PLT at the first eltrombopag administration was 30 × 10/L. The median follow-up was 7 months (range, 3–22 months). After 1 week of treatment, response (R) was noted in 53.3% (95% confidence interval [CI]: 40.7%–66.0%) patients, and complete response (CR) was seen in 21.6% (95% CI: 11.2%–32.1%). We evaluated the long-term duration of the response and found that it was obtained in 84.4% (95% CI: 71.8%–97.0%) and 88.9% (95% CI: 77.0%–100%) of patients after 6 and 12 months, respectively, of eltrombopag therapy, while CR was reached, respectively, in 46.9% (95% CI: 29.6%–64.2%) and 29.6% (95% CI: 12.4%–46.9%) patients. No serious adverse events were reported.

Conclusion

Our data support the safety and efficacy of eltrombopag use in cITP pediatric patients.

Abstract

Background

Thrombopoietin receptor agonists have been repeatedly confirmed to be safe, efficient, and well tolerated in pediatric patients with chronic immune thrombocytopenia (cITP).

Material and methods

In this report, we present data summarizing the Polish experience of the use of eltrombopag in cITP patients, refractory to standard first-line care. Our analysis was based on clinical and epidemiological data from the Nationwide Therapeutic Program 2018–2020. Quality of the response to the eltrombopag treatment was defined according to the International Consensus Guidelines as follows: complete response (CR) defined as platelet count (PLT) ≥100 × 10/L and absence of bleeding; response (R) defined as PLT ≥30 × 10/L and at least two-fold increase in the baseline count and absence of bleeding.

Results

We evaluated 60 patients (33 boys and 27 girls) with chronic and refractory ITP. Median age at beginning of treatment was 9.5 years. Median PLT at the first eltrombopag administration was 30 × 10/L. The median follow-up was 7 months (range, 3–22 months). After 1 week of treatment, response (R) was noted in 53.3% (95% confidence interval [CI]: 40.7%–66.0%) patients, and complete response (CR) was seen in 21.6% (95% CI: 11.2%–32.1%). We evaluated the long-term duration of the response and found that it was obtained in 84.4% (95% CI: 71.8%–97.0%) and 88.9% (95% CI: 77.0%–100%) of patients after 6 and 12 months, respectively, of eltrombopag therapy, while CR was reached, respectively, in 46.9% (95% CI: 29.6%–64.2%) and 29.6% (95% CI: 12.4%–46.9%) patients. No serious adverse events were reported.

Conclusion

Our data support the safety and efficacy of eltrombopag use in cITP pediatric patients.

Get Citation

Keywords

chronic immune thrombocytopenia; childhood; eltrombopag

About this article
Title

Eltrombopag use in chronic immune thrombocytopenia of childhood: results from nationwide therapeutic program

Journal

Acta Haematologica Polonica

Issue

Vol 51, No 4 (2020)

Pages

226-229

Published online

2020-12-01

DOI

10.2478/ahp-2020-0039

Bibliographic record

Acta Haematol Pol 2020;51(4):226-229.

Keywords

chronic immune thrombocytopenia
childhood
eltrombopag

Authors

Monika Richert-Przygońska
Ewa Demidowicz
Natalia Bartoszewicz
Krzysztof Czyżewski
Mariusz Wysocki
Jan Styczyński

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl